On Thursday, Edwards Lifesciences (EW) stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 75.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the market's biggest winners often have an 80 or higher RS Rating as they launch their largest price moves. See if Edwards Lifesciences stock can continue to show renewed price strength and clear that threshold.
Edward Lifesciences stock broke out of a flat base on July 25. It's slightly extended and not currently an ideal time to buy shares, see if the stock goes on to offer and clear an appropriate buy point.
Earnings growth decreased last quarter from 16% to 8%. But revenue gains moved higher, from 6% to 12%.
Edwards Lifesciences stock earns the No. 10 rank among its peers in the Medical-Products industry group. Insulet (PODD), TransMedics Group (TMDX) and ResMed (RMD) are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
YOU MAY ALSO LIKE:
Hone Your Investing Skills Online — For Free — With IBD Meetups
Learn How To Invest: Join An Online IBD Meetup Group
Join An IBD Meetup Group — Online From Anywhere
Ready To Grow Your Investing Skills? Join An IBD Meetup Group
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。